New findings seen in the CorEvitas Psoriatic Arthritis (PsA) and Spondyloarthritis Registry indicate that a significant number of those with treatment-resistant active psoriatic arthritis (PsA) treated through 6 months with guselkumab in real-world settings showed improvements in physical function, pain, and fatigue.^1,2,3

This data from Janssen Pharmaceuticals, Inc., was presented at the 2023 American College of Rheumatology (ACR) Annual Convergence. In this interview with the HCPLive editorial team, Philip J. Mease, MD, clinical professor at the University of Washington School of Medicine and director of rheumatology research at the Swedish Medical Center in Seattle, spoke on the new findings.

“There are over 50 sites around the country that are contributing patients on a regular basis, who are being started on a variety of different treatments,” Mease explained. “And it's a way of really seeing what happens with these patients over time. How severe is their disease? What's the impact of their condition? How are they responding to treatments or their side effects?”

In the findings from the DISCOVER-1, DISCOVER-2, and COSMOS clinical trials, investigators found that guselkumab use was linked to higher rates of clinically meaningful improvements in patient-reported fatigue, skin issues, pain, physical function, and PsA-related depression versus those in the placebo arm.

“So in all these ways that are sort of simple, but important ways of assessing the drug’s impact on pain function, and global, they improved,” Mease said. “And so I think this supports the data that we have seen from phase 3 clinical trials that show that the drug really impacts patients in a way that we like to see.”

For further information, view the full interview segment above or other ACR 2023 conference coverage.

Mease is a paid consultant for Janssen and was not compensated for media work. The quotes used in this summary were edited for the purposes of clarity.

References

1. ^{Mease PJ, et al. Improvements in Patient-Reported Outcomes Through 6 Months of Guselkumab Treatment in Patients With Active Psoriatic Arthritis: Real-World Data From the CorEvitas Psoriatic Arthritis/Spondyloarthritis (PsA/SpA) Registry. Presented at ACR Convergence 2023, Nov. 10-15.}
2. ^{Selmi C, et al. Longitudinal Evaluation of the Novel Psoriatic Arthritis 5-Thermometer Scale (PsA-5Ts) Domains During Treatment with Guselkumab: Pooled Analysis of Three Phase 3, Randomized, Double-blind, Placebo-Controlled Studies. Presented at ACR Convergence 2023, Nov. 10-15.}
3. ^{Food and Drug Administration. TREMFYA® Prescribing Information. Horsham, PA. 2017. Available at: https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/TREMFYA-pi.pdf. Accessed November 2023.}